Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07191561 · ClinicalTrials.gov registry record
Hepatic Lipid Metabolism-Alcohol Use Disorder
A clinical trial, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Recruiting
- Registry status
- 25
- Enrollment target
NCT07191561: Recruiting study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT07191561 is a clinical trial that is actively recruiting participants, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07191561 is actively recruiting participants, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
Study Summary
Patients with hepatic steatosis due to alcohol will be offered liver biopsies when they enter a detoxification program. The first biopsy will occur in the first week of admission and the second in the fourth week when the steatosis has resolved. The hepatic transcriptome will be compared,
Primary Outcome
Analysis of liver biopsies
Interventions
- DIAGNOSTIC_TEST Liver biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2029-11-30 |
What NCT07191561 shows while recruiting
NCT07191561 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Liver biopsy is the first listed.
NCT07191561 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07191561 about?
NCT07191561 is a clinical study titled "Hepatic Lipid Metabolism-Alcohol Use Disorder". Patients with hepatic steatosis due to alcohol will be offered liver biopsies when they enter a detoxification program. The first biopsy will occur in the first week of admission and the second in the fourth week when the steatosis has resolved. The hepatic transcriptome will be compared,
What is the current status of trial NCT07191561?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2026-07-15. Estimated completion is 2029-11-30.
What interventions are being tested in trial NCT07191561?
The interventions under investigation include: Liver biopsy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07191561?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI